Bruker (BRKR) AI Stock Analysis

• Market Cap: $5.14B
• Dividend Yield: 0.42%
• Average Volume (3M): 2.32M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.20
• Revenue Growth: 6.10%
• EPS Growth: -107.47%
• Country: US
• Employees: 11,396
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.59
• Shares Outstanding: 152,219,250
• 10 Day Avg. Volume: 2,055,339
• 30 Day Avg. Volume: 2,322,450
• PEG Ratio: 6.94
• Price to Book (P/B): 2.91
• Price to Sales (P/S): 2.08
• P/FCF Ratio: 165.16
• Enterprise Value/Market Cap: 1.34
• Enterprise Value/Revenue: 2.00
• Enterprise Value/Gross Profit: 4.30
• Enterprise Value/Ebitda: 23.15
• 1Y Price Target: $45.00
• Price Target Upside: 33.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): 2.12
• Revenue Forecast (FY): $3.57B

• Rating: 51 Neutral
• Price Target: $34.00 ▲(0.74% Upside)
• Action: Reiterated Date: 02/22/26
• Date: Action: Reiterated 02/22/26

BRKR scores in the low-50s primarily due to weakened TTM fundamentals (revenue decline, margin compression, and materially softer operating/free cash flow) and bearish technicals (price below key moving averages with negative MACD). The latest earnings call provides partial support via constructive FY2026 margin/EPS guidance and strong backlog/cash generation, but near-term organic declines and execution/headwind risks keep the overall score restrained; valuation support is limited by a negative P/E and only a modest dividend yield.

Positive Factors

Recurring Aftermarket Revenue

A higher aftermarket mix (38% of BSI) increases recurring revenue and reduces reliance on lumpy instrument placements. Durable service, consumables and software sales support steadier margins and cash flows across equipment cycles, improving long-term revenue stability and predictability.

Order Momentum & Backlog

A book-to-bill above 1.0 and ~7 months of backlog provide multi-quarter revenue visibility and indicate demand recovery. This structural backlog cushions near-term cyclicality in instrument sales, supports sustained revenue conversion, and underpins cash generation as orders convert to shipments.

Structural Cost Savings & Margin Plan

Project Accelerate targeting $140M+ annualized savings and management's 250–300 bps margin expansion guidance imply structural cost base improvement. Realized savings increase operating leverage, making future revenue growth more profitable and strengthening medium‑term free cash flow sustainability.

Negative Factors

Revenue & Margin Weakness

A TTM revenue decline of ~7% and substantial margin compression that produced a small net loss signal weakened demand and impaired operating leverage. Persistent top-line pressure reduces scale benefits, increases execution risk, and requires sustained improvement to restore profitability and returns.

Weakened Cash Conversion

Material decline in operating cash flow and FCF versus prior years reduces internal funding for R&D, capex, and debt reduction. Inconsistent cash conversion heightens reliance on cost programs and makes strategic investments or debt paydown more difficult without sustained margin recovery or structural revenue improvement.

End‑Market & Macro Exposure

Significant exposure to academic/government funding and cyclical markets (NMR, superconducting MRI) creates sensitivity to budget cycles and funding volatility. Combined with tariffs and FX headwinds, this structural exposure can prolong organic weakness and pressure margins until end‑market recovery.

Bruker Business Overview & Revenue Model

Company Description

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

How the Company Makes Money

Bruker primarily makes money by selling scientific instruments and integrated analytical systems, complemented by recurring revenue from services, software, and consumables. Key revenue streams typically include: (1) Instrument and system sales: One-time (often high-value) sales of analytical and diagnostic instruments and complete systems to customers such as academic and government research labs, pharmaceutical and biotechnology companies, industrial manufacturers, and clinical/diagnostic labs. These sales can be project- and capital-budget driven and may include customized configurations and bundled components. (2) Services and maintenance: Ongoing revenue from installation, calibration/validation support, preventive maintenance, repairs, extended warranties, and service contracts that support the installed base of instruments. Service revenue tends to be more recurring than instrument revenue and can scale with the size and utilization of the installed base. (3) Consumables and accessories: Repeat purchases such as reagents, sample preparation items, columns, standards, targets, probes, and replacement parts/accessories used with Bruker instruments. Consumables revenue is usage-driven and can provide a recurring stream tied to customer throughput. (4) Software and informatics: Revenue from instrument control software, data processing/analysis tools, licenses, subscriptions (where offered), and upgrades that enhance workflows and integrate data into customer environments. (5) Method development, applications support, and specialized solutions: Bruker can generate additional revenue through application-specific packages and workflow solutions (e.g., for proteomics, metabolomics, biopharma characterization, materials characterization) that bundle hardware, software, and services. Overall, Bruker’s earnings are driven by a mix of capital equipment cycles (instrument/system placements) and recurring/aftermarket revenue (service contracts, consumables, software), with growth influenced by research funding levels, pharma/biotech R&D and manufacturing demand, industrial quality/control requirements, and adoption of advanced analytical techniques. Specific partnership details: null.

Bruker Financial Statement Overview

Summary

Financial performance is pressured in TTM: revenue declined (-7%), operating/EBITDA margins compressed sharply versus 2023–2024, and results slipped to a small net loss. The balance sheet is a relative bright spot with improved debt-to-equity (~0.76 in TTM vs ~1.26 in 2024), but cash generation weakened materially (operating cash flow down to ~$134M; free cash flow ~$43M), increasing execution risk until margins and cash conversion recover.

Income Statement

Revenue growth has decelerated meaningfully, moving from strong growth in 2021–2024 to a decline in TTM (Trailing-Twelve-Months) (-7%). Profitability also compressed sharply: TTM operating and EBITDA margins are down substantially versus 2023–2024 levels, and net results slipped to a small loss in TTM after remaining profitable in prior annual periods. The key strength is that gross margin remains relatively resilient in the mid-to-high 40% range, but the weaker operating leverage and negative net margin in TTM weigh on the score.

Balance Sheet

Leverage has improved versus 2024, with debt-to-equity declining from ~1.26 (2024) to ~0.76 in TTM (Trailing-Twelve-Months), supported by a higher equity base. That said, total debt remains sizable (~$1.87B), and returns to shareholders turned slightly negative in TTM alongside the net loss. Overall, the balance sheet looks more stable than last year, but profitability-driven pressure on returns remains a risk.

Cash Flow

Cash generation weakened materially in TTM (Trailing-Twelve-Months): operating cash flow fell to ~$134M from ~$251M in 2024 and ~$350M in 2023, while free cash flow dropped to ~$43M. Free cash flow also shows a sharp negative growth rate in TTM, indicating significant deterioration versus the prior period. A positive is that cash flow remains positive despite the small TTM net loss, but overall cash conversion and consistency have clearly softened.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.44B	3.37B	2.96B	2.53B	2.42B
Gross Profit	1.57B	1.65B	1.51B	1.31B	1.21B
EBITDA	287.50M	438.60M	675.50M	518.70M	497.10M
Net Income	-8.60M	113.10M	427.20M	296.60M	277.10M
Balance Sheet
Total Assets	6.24B	5.81B	4.25B	3.61B	3.65B
Cash, Cash Equivalents and Short-Term Investments	298.80M	183.40M	488.30M	645.50M	1.17B
Total Debt	2.04B	2.25B	1.38B	1.27B	1.39B
Total Liabilities	3.73B	3.99B	2.84B	2.48B	2.57B
Stockholders Equity	2.46B	1.78B	1.38B	1.11B	1.07B
Cash Flow
Free Cash Flow	43.30M	136.00M	243.20M	145.20M	190.40M
Operating Cash Flow	134.10M	251.30M	350.10M	274.40M	282.40M
Investing Cash Flow	-196.50M	-1.76B	-326.00M	-251.60M	-192.40M
Financing Cash Flow	135.10M	1.23B	-193.40M	-415.30M	318.70M

Bruker Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 33.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRKR, the sentiment is Negative. The current price of 33.75 is below the 20-day moving average (MA) of 38.20, below the 50-day MA of 43.71, and below the 200-day MA of 40.04, indicating a bearish trend. The MACD of -2.09 indicates Positive momentum. The RSI at 27.23 is Positive, neither overbought nor oversold. The STOCH value of 7.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BRKR.

Bruker Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GMED	80 Outperform	$11.45B	21.94	10.01%	―	11.75%	364.73%
LIVN	68 Neutral	$3.20B	-13.83	-21.49%	―	8.97%	-1024.86%
ITGR	66 Neutral	$2.86B	26.50	6.05%	―	7.81%	-26.32%
BIO	64 Neutral	$7.10B	10.87	10.86%	―	-0.88%	10.93%
GKOS	59 Neutral	$5.63B	-34.40	-25.41%	―	30.38%	47.64%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BRKR	51 Neutral	$5.14B	-831.55	-0.40%	0.42%	6.10%	-107.47%

Bruker Corporate Events

Bruker Announces Board Changes and Declares Quarterly Dividend

On February 16, 2026, Bruker said board member Dr. Cynthia M. Friend will retire from the Board of Directors at the 2026 Annual Meeting when her current term as a Class II director expires, after serving since May 2016 and sitting on the Compensation Committee, with the company emphasizing her decision was not related to any disagreement and that she will serve out her term. On February 19, 2026, the Board reclassified Jack Phillips from a Class III to a Class II director with his board service deemed continuous from January 1, 2026, positioning him for re-election at the 2026 Annual Meeting, and on the same day it declared a quarterly cash dividend of $0.05 per share, payable on April 7, 2026, to shareholders of record as of March 23, 2026, underscoring ongoing capital returns alongside orderly board transition planning.

The most recent analyst rating on (BRKR) stock is a Hold with a $38.00 price target. To see the full list of analyst forecasts on Bruker stock, see the BRKR Stock Forecast page.

Bruker clarifies regulatory filing status in recent 8-K

In a recent regulatory filing, Bruker clarified that certain information furnished in Item 2.02 and Item 7.01 of its current report on Form 8-K is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 and will not automatically be incorporated into other securities law filings. This delineation underscores the company’s intent to limit potential legal exposure and maintain control over how specific disclosures are referenced in future filings, which is relevant for investors and other stakeholders tracking the legal and regulatory status of its reported information.

The most recent analyst rating on (BRKR) stock is a Hold with a $53.00 price target. To see the full list of analyst forecasts on Bruker stock, see the BRKR Stock Forecast page.